Tempus AI, Inc. - Class A Common Stock (TEM)

54.04
-5.57 (-9.34%)
NASDAQ · Last Trade: Nov 21st, 6:11 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Natera vs. Tempus AI: Which Blood Test Pioneer Has the Better Stock Buy for 2027?fool.com
Natera's revenue growth tops 37%, but Tempus AI trades at a lower forward multiple, and the balance sheets and cash flow stories diverge sharply.
Via The Motley Fool · November 19, 2026
Grail vs. Tempus AI: Which Healthcare Stock Is a Better Buy for 2027?fool.com
Grail's cancer blood test faces a setback in a major UK trial, while Tempus AI's data business is growing fast but still losing money. The two carry very different risk profiles.
Via The Motley Fool · November 19, 2026
Tempus AI: 3 Key Takeaways for Long-Term Investorsfool.com
Positive adjusted EBITDA signals the diagnostic platform has crossed a profitability threshold where test volume growth flows directly to earnings.
Via The Motley Fool · November 19, 2026
The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boommarketbeat.com
AI infrastructure is being funded with debt and stock sales while biotech companies applying AI are booking revenue, led by Tempus AI, Recursion and iShares Biotechnology
Via MarketBeat · November 11, 2026
Can Cathie Wood's Ark Invest ETF Make a Comeback With Its Large SpaceX Position?fool.com
SpaceX will make the Ark Innovation ETF more volatile, and AI trends ultimately determine the fund's fate.
Via The Motley Fool · November 11, 2026
MarketBeat Week in Review – 11/2 - 11/6marketbeat.com
Via MarketBeat · November 7, 2026
Tempus AI Surges on Earnings Beat, But Can the Rally Last?marketbeat.com
Tempus AI posted Q3 revenue up 23.1% and a surprise profit, raised guidance, and saw shares surge 10%, though analysts cite cash burn and limited 2026 upside.
Via MarketBeat · November 3, 2026
Tempus (TEM) Q3 2026 Earnings Call Transcriptfool.com
Oncology volume surged 32% while data licensing bookings topped $550 million year-to-date.
Via The Motley Fool · November 2, 2026
Tempus AI Revenue Up 23%; Gains Cut Net Loss: Rapid Earnings Reactionfool.com
Tempus AI raised its outlook on 23% revenue growth, but most of its smaller net loss came from paper gains on stock it holds, not the core business.
Via The Motley Fool · November 2, 2026
What Tempus AI (TEM) Said on Its Q3 Earnings Callmarketbeat.com
Tempus AI (NASDAQ:TEM) reported third-quarter 2026 revenue of $411.5 million, up 23% from a year earlier, as growth in oncology diagnostics and data-and-applications services continued to drive results. The company also raised its full-year revenue outlook and said it generated positive adjusted EBI
Via MarketBeat · November 2, 2026
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winningmarketbeat.com
AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.
Via MarketBeat · October 19, 2026
Tempus AI Chief Accounting Officer Sells $529,650 of Stockfool.com
Sale follows 30% rebound in the stock year to date.
Via The Motley Fool · September 24, 2026
Tempus AI Sees Pricing, Data Growth Fueling Long-Term Expansionmarketbeat.com
Tempus AI (NASDAQ:TEM) Founder and CEO Eric Lefkofsky said the company’s second-quarter performance was supported by continued demand for comprehensive genomic profiling and growth in its data-licensing business. Speaking at Morgan Stanley’s Global Healthcare Conference, Lefkofsky said the diagnost
Via MarketBeat · September 21, 2026
Tempus AI Director Nadja West Sells 3,000 Shares for $207,000fool.com
Sale executed under pre-established Rule 10b5-1 trading plan adopted in May, leaving West with 31,981 shares and a 0.0183% ownership stake.
Via The Motley Fool · September 2, 2026
Cathie Wood Invested Roughly $1.4 Billion of Ark Invest's Flagship ETF in Just 3 Artificial Intelligence (AI) Stocksfool.com
Wood is known for being a tech-first investor.
Via The Motley Fool · August 28, 2026
Why Tempus AI Skyrocketed This Weekfool.com
Tempus AI's latest acquisition is looking like a great move.
Via The Motley Fool · August 23, 2026
A Tempus AI Director Sold Stock Four Days Before a 24% Rally. Here's What to Knowfool.com
West executed a sale under a pre-established Rule 10b5-1 trading plan, reducing her direct stake by 8% while retaining 34,981 shares worth roughly $1.8 million.
Via The Motley Fool · August 22, 2026
Is Tempus AI Stock a Buy After Its 75% Rally? Here's What to Know as the Firm's Legal Chief Files a Tradefool.com
Polovin's sale of 30,075 shares was non-discretionary and tied to tax withholding from RSU vesting.
Via The Motley Fool · August 22, 2026
Tempus AI's Accounting Chief Just Reported an Insider Transaction. Here's What Long-Term Investors Should Knowfool.com
Bartolucci disposed of shares valued at $306,342 to cover statutory withholding obligations tied to RSU vesting, retaining direct holdings of 67,866 shares worth $3.35 million.
Via The Motley Fool · August 22, 2026
What to Know About the CFO of Tempus AI's Latest Insider Transaction Filingfool.com
This non-discretionary sale to cover RSU withholding obligations reduced his direct stake, but he retains about 106,000 shares valued at $6.49 million.
Via The Motley Fool · August 22, 2026
Tempus AI's Diagnostics Chief Filed Stock Sales Spanning a Volatile Week. Here's What Happenedfool.com
These sales were driven by tax withholding obligations tied to restricted stock unit vesting under a pre-established trading plan.
Via The Motley Fool · August 22, 2026
Tempus AI's Data Chief Just Filed a Form 4. His Segment Grew 28% Last Quarter.fool.com
This sale was non-discretionary, executed to cover tax withholding from RSU vesting.
Via The Motley Fool · August 22, 2026
Tempus AI's CEO Sold $6.6 Million in Stock the Day Before a Huge Rally. Here's What to Knowfool.com
This filing details a non-discretionary sale that reduced Lefkofsky's direct holdings by a small percentage.
Via The Motley Fool · August 22, 2026
Why Is Tempus AI Stock Surging on Friday?benzinga.com
Tempus AI Inc. (NASDAQ: TEM) stock jumped on Friday, August 7, 2026, following strong AI healthcare peer earnings from Doximity Inc. and a strategic lab expansion with CellCarta.
Via Benzinga · August 7, 2026
Tempus AI Q2 Earnings Call Highlightsmarketbeat.com
Tempus AI (NASDAQ:TEM) reported second-quarter revenue growth of 22% and raised its full-year outlook, citing accelerating oncology testing volumes, expanding demand for its data and artificial intelligence offerings, and expected reimbursement benefits from newly approved diagnostic products. Reve
Via MarketBeat · July 31, 2026